97 related articles for article (PubMed ID: 23955683)
1. Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis.
Mohsenzadegan M; Madjd Z; Asgari M; Abolhasani M; Shekarabi M; Taeb J; Shariftabrizi A
Cancer Immunol Immunother; 2013 Oct; 62(10):1609-18. PubMed ID: 23955683
[TBL] [Abstract][Full Text] [Related]
2. NGEP, a prostate-specific plasma membrane protein that promotes the association of LNCaP cells.
Das S; Hahn Y; Nagata S; Willingham MC; Bera TK; Lee B; Pastan I
Cancer Res; 2007 Feb; 67(4):1594-601. PubMed ID: 17308099
[TBL] [Abstract][Full Text] [Related]
3. Study of NGEP expression pattern in cancerous tissues provides novel insights into prognostic marker in prostate cancer.
Mohsenzadegan M; Shekarabi M; Madjd Z; Asgari M; Abolhasani M; Tajik N; Farajollahi MM
Biomark Med; 2015; 9(4):391-401. PubMed ID: 25808443
[TBL] [Abstract][Full Text] [Related]
4. Expression of prostate stem cell antigen (PSCA) in prostate cancer: a tissue microarray study of Iranian patients.
Taeb J; Asgari M; Abolhasani M; Farajollahi MM; Madjd Z
Pathol Res Pract; 2014 Jan; 210(1):18-23. PubMed ID: 24183365
[TBL] [Abstract][Full Text] [Related]
5. NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate.
Bera TK; Das S; Maeda H; Beers R; Wolfgang CD; Kumar V; Hahn Y; Lee B; Pastan I
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3059-64. PubMed ID: 14981236
[TBL] [Abstract][Full Text] [Related]
6. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of global DNA hypomethylation in human prostate cancer and prostatic intraepithelial neoplasm tissues by immunohistochemistry.
Yang B; Sun H; Lin W; Hou W; Li H; Zhang L; Li F; Gu Y; Song Y; Li Q; Zhang F
Urol Oncol; 2013 Jul; 31(5):628-34. PubMed ID: 21704537
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic significance of overexpression of Golgi membrane protein 1 in prostate cancer.
Li W; Wang X; Li B; Lu J; Chen G
Urology; 2012 Oct; 80(4):952.e1-7. PubMed ID: 22840862
[TBL] [Abstract][Full Text] [Related]
10. Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer.
Miyake M; Lawton A; Goodison S; Urquidi V; Rosser CJ
Pathol Res Pract; 2014 Feb; 210(2):74-8. PubMed ID: 24252309
[TBL] [Abstract][Full Text] [Related]
11. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
13. New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
Cereda V; Poole DJ; Palena C; Das S; Bera TK; Remondo C; Gulley JL; Arlen PM; Yokokawa J; Pastan I; Schlom J; Tsang KY
Cancer Immunol Immunother; 2010 Jan; 59(1):63-71. PubMed ID: 19495750
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer.
Arencibia JM; Martín S; Pérez-Rodríguez FJ; Bonnin A
Int J Oncol; 2009 Feb; 34(2):457-63. PubMed ID: 19148481
[TBL] [Abstract][Full Text] [Related]
15. Identification of PCAG1 as a novel prostate cancer-associated gene.
Lai Y; Yu Z; Wang Y; Ye J
Mol Med Rep; 2013 Mar; 7(3):755-60. PubMed ID: 23292432
[TBL] [Abstract][Full Text] [Related]
16. High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.
Ruiz C; Oeggerli M; Germann M; Gluderer S; Stocker H; Andreozzi M; Thalmann GN; Cecchini MG; Zellweger T; Stürm S; Koivisto PA; Helin HJ; Gelmann EP; Glass AG; Gasser TC; Terracciano LM; Bachmann A; Wyler S; Bubendorf L; Rentsch CA
Prostate; 2012 Nov; 72(15):1678-87. PubMed ID: 22473923
[TBL] [Abstract][Full Text] [Related]
17. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence.
Seligson DB; Hongo F; Huerta-Yepez S; Mizutani Y; Miki T; Yu H; Horvath S; Chia D; Goodglick L; Bonavida B
Clin Cancer Res; 2007 Oct; 13(20):6056-63. PubMed ID: 17947468
[TBL] [Abstract][Full Text] [Related]
18. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
[TBL] [Abstract][Full Text] [Related]
19. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
Imasato Y; Xuan JW; Sakai H; Izawa JI; Saito Y; Chin JL; Moussa M
J Urol; 2000 Nov; 164(5):1819-24. PubMed ID: 11025776
[TBL] [Abstract][Full Text] [Related]
20. The E2F1/DNMT1 axis is associated with the development of AR negative castration resistant prostate cancer.
Valdez CD; Kunju L; Daignault S; Wojno KJ; Day ML
Prostate; 2013 Dec; 73(16):1776-85. PubMed ID: 24038143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
